AIRNA is a startup based in the United States. Its most recent tracked round is Series B. Brouky records 5 investors associated with the company.
AIRNA is developing RNA-editing therapeutics to treat rare and common diseases, with a focus on delivering functional cures through precise genetic modifications.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.